ReviewFrontiers in immunology2025

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.

Jie Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.